Ziftomenib is an investigational drug in development for the treatment of patients withacute myeloid leukemia (AML) with eligible genetic alterations. Ziftomenib is a type oftherapy known to target the menin pathway in cancer cells.This protocol has 2 separate studies that will investigate the benefits and risks ofadding ziftomenib to standard-of-care (SOC) AML treatments in patients with certaingenetic mutations who have not received any treatment for their AML. In the first study,the Nonintensive Therapy Study, older patients or those with serious medical problemswill receive the SOC therapies venetoclax (ven) and azacitidine (aza), plus eitherziftomenib or a placebo. In the second study, the Intensive Therapy Study, medically fitpatients will receive (a) the SOC therapies cytarabine and daunorubicin, plus eitherziftomenib or a placebo during a first treatment phase called induction, (b) cytarabineplus either ziftomenib or a placebo during a second treatment phase called consolidation,and (c) ziftomenib or a placebo during a third treatment phase called maintenance.The physician will determine which study is the appropriate treatment for the patient,but neither the patient nor their physician will know whether the patient has beenassigned to receive ziftomenib or a placebo. This design is called "double-blinded".
This protocol encompasses two phase 3, randomized, double-blind, placebo-controlled
clinical studies to assess the efficacy, safety, and tolerability of ziftomenib in
combination with: (a) the standard of care (SOC) nonintensive regimen (venetoclax
[ven]+azacitidine [aza]) in untreated adults with nucleophosmin 1 mutated (NPM1-m) acute
myeloid leukemia (AML); or (b) the SOC intensive regimen (cytarabine+daunorubicin
induction, referred to here as 7+3, and cytarabine consolidation) in untreated adults
with NPM1-m or lysine[K]-specific methyltransferase 2A rearranged (KMT2A-r) AML, as well
as a maintenance phase.
Nonintensive Therapy Study (Ven+Aza)
Eligible NPM1-m patients will be enrolled and randomized to receive:
- Arm A: Ziftomenib in combination with ven+aza or
- Arm B: Placebo in combination with ven+aza.
Patients will be randomized to treatment arms in a double-blind manner.
Intensive Therapy Study (Cytarabine+Daunorubicin)
Eligible NPM1-m or KMT2A-r patients will be enrolled and randomized to 1 of the following
treatment arms:
- Arm A: Ziftomenib+7+3 (induction), ziftomenib+cytarabine (consolidation), ziftomenib
(maintenance) or
- Arm B: Ziftomenib+7+3 (induction), ziftomenib+cytarabine (consolidation), placebo
(maintenance) or
- Arm C: Placebo+7+3 (induction), placebo+cytarabine (consolidation), placebo
(maintenance).
Patients will be randomized to treatment arms in a double-blind manner.
Drug: Ziftomenib
Oral administration
Other Name: KO-539
Drug: Placebo
Oral administration
Drug: Venetoclax
Oral administration
Other Name: Venclexta,Venclyxto
Drug: Azacitidine (AZA)
Intravenous or subcutaneous administration
Other Name: Vidaza,Azadine
Drug: Daunorubicin
Intravenous administration
Other Name: Cerubidine,daunomycin
Drug: Cytarabine (Ara-C)
Intravenous administration
Other Name: cytosine arabinoside (ara-C),Cytosar-U,Tarabine PFS
Key Inclusion Criteria:
The following criteria apply to both the Nonintensive Therapy Study and the Intensive
Therapy Study unless otherwise noted:
- Age ≥18 years at time of signing the informed consent form.
- Diagnosis of AML per the 2022 WHO Classification of Hematolymphoid Tumors (5th
Edition).
- Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.
- Adequate liver and kidney function according to protocol requirements.
- A female of childbearing potential must agree to use adequate contraception from the
time of screening through 180 days following the last dose of study intervention. A
male with a female partner of childbearing potential must agree to use abstinence or
adequate contraception from the time of screening through 90 days following the last
dose of study intervention.
- NONINTENSIVE THERAPY STUDY ONLY (VEN+AZA):
1. Documented NPM1-m.
2. Patients considered ineligible for Intensive Therapy defined by the following:
- i. Age ≥75, OR
- ii. Age <75 with an ECOG performance status of 2 or cardiac, renal, or
hepatic impairment per protocol criteria.
- INTENSIVE THERAPY STUDY ONLY (7+3):
1. Documented NPM1-m or KMT2A-r (KMT2A-r patients with a partial tandem
duplication are not eligible).
2. Documented FLT3 wild-type or ITD ratio <0.05 OR ineligible to receive
FLT3-targeted therapy (medically ineligible or mutation in which FLT3
inhibition is not SOC). Lack of access to an FLT3 inhibitor is not considered
"ineligible" for FLT3-targeted therapy.
3. Ejection fraction of ≥50%.
4. Fit for Intensive Therapy per Investigator opinion.
Key Exclusion Criteria:
- Prior therapy for AML (except hydroxyurea or leukapheresis for WBC control).
- Diagnosis of acute promyelocytic leukemia (APL), blast phase chronic myeloid
leukemia, or isolated myeloid sarcoma.
- Known history of BCR-ABL mutation.
- History of other active concurrent malignancies prior to study entry except:
1. Basal cell skin cancer or localized squamous cell cancer of the skin
2. Previous malignancy confined and locally resected (or treated with other
modalities) with curative intent
3. Prostate or breast cancer receiving adjuvant hormonal therapy.
- Active central nervous system (CNS) involvement by AML.
- Clinical signs/symptoms of leukostasis or white blood cells (WBC) >25×10^9/L prior
to start of ziftomenib/placebo. Note: Hydroxyurea and/or leukapheresis are permitted
to meet this criterion.
- Known uncontrolled HIV infection or known active hepatitis B virus, hepatitis C
virus infection, or other uncontrolled infection.
- Uncontrolled intercurrent illness including but not limited to, cardiac illness as
defined in the protocol.
- Women who are pregnant or lactating.
Banner MD Anderson Cancer Center
Gilbert, Arizona, United States
University of California, Fresno
Clovis, California, United States
University of California, San Diego
La Jolla, California, United States
Cedars-Sinai Medical Center
Los Angeles, California, United States
University of California, Los Angeles
Los Angeles, California, United States
University of California, Irvine
Orange, California, United States
University of Colorado
Aurora, Colorado, United States
Colorado Blood Cancer Institute
Denver, Colorado, United States
Hartford HealthCare Cancer Institute
Hartford, Connecticut, United States
Yale University School of Medicine
New Haven, Connecticut, United States
University of Miami
Miami, Florida, United States
Moffitt Cancer Center & Research Institute
Tampa, Florida, United States
University of Iowa
Iowa City, Iowa, United States
University of Kentucky
Lexington, Kentucky, United States
University of Massachusetts
Worcester, Massachusetts, United States
University of Michigan
Ann Arbor, Michigan, United States
Wayne State University School of Medicine
Detroit, Michigan, United States
University of Minnesota
Minneapolis, Minnesota, United States
Rutgers Biomedical and Health Sciences
New Brunswick, New Jersey, United States
University of New Mexico
Albuquerque, New Mexico, United States
State University of New York at Buffalo
Buffalo, New York, United States
Icahn School of Medicine at Mount Sinai
New York, New York, United States
Columbia University
New York, New York, United States
Weill Cornell Medical Center
New York, New York, United States
University of North Carolina, Chapel Hill
Chapel Hill, North Carolina, United States
Duke University Medical Center
Durham, North Carolina, United States
Ohio State University
Columbus, Ohio, United States
Willamette Valley Cancer Institute
Eugene, Oregon, United States
University of Pennsylvania
Philadelphia, Pennsylvania, United States
Baptist Clinical Research Institute
Memphis, Tennessee, United States
Tennessee Oncology
Nashville, Tennessee, United States
TriStar Centennial Medical Center
Nashville, Tennessee, United States
Texas Oncology-Austin Midtown
Austin, Texas, United States
Texas Oncology-Presbyterian Cancer Center
Dallas, Texas, United States
University of Texas
Houston, Texas, United States
Texas Oncology - San Antonio Medical Center
San Antonio, Texas, United States
University of Vermont Medical Center
Burlington, Vermont, United States
University of Virginia School of Medicine
Charlottesville, Virginia, United States
Virginia Cancer Specialists
Manassas, Virginia, United States
WVU Medicine Wheeling Hospital
Wheeling, West Virginia, United States
University of Wisconsin
Madison, Wisconsin, United States
Froedtert & Medical College of Wisconsin
Milwaukee, Wisconsin, United States
Fakultní Nemocnice Královské Vinohrady
Prague, Prague, Czechia
Hôpital Lyon Sud
Pierre-Bénite, Auvergne-Rhône-Alpes, France
Hôpital Universitaire Henri Mondor
Créteil, Val-de-Marne, France
Centre Hospitalier de Béziers
Béziers, France
Groupe Hospitalier de la Region de Mulhouse et Sud Alsace Hôpital Emile Muller
Mulhouse, France
Centre Hospitalier Universitaire de Nantes
Nantes, France
Centre Hospitalier Universitaire de Saint Etienne
Saint-Priest-en-Jarez, France
Centre Hospitalier Régional et Universitaire de Nancy Hôpitaux de Brabois
Vandœuvre-lès-Nancy, France
Hôpital Saint Louis
Paris, Île-de-France Region, France
Helios Klinikum Bad Saarow
Bad Saarow, Germany
Azienda Sanitaria Territoriale di Ascoli Piceno
Ascoli Piceno, The Marches, Italy
L'IRCCS Azienda Ospedaliero - Universitaria di Bologna
Bologna, Italy
Baguio General Hospital and Medical Center
Baguio City, Benguet, Philippines
Hospital de Braga, Centro Clínico Académico de Braga
Braga, Portugal
Anam Hospital Korea University
Seoul, Seoul-T'Ukpyolshi, South Korea
Samsung Medical Center
Seoul, Seoul-T'Ukpyolshi, South Korea
Dong-A University Hospital
Busan, South Korea
Busan National University Hospital
Busan, South Korea
Chungnam National University Daejeon Hospital
Daejeon, South Korea
Chonnam National University Hwasun Hospital
Hwasun, South Korea
Ulsan University Hospital
Ulsan, South Korea
Hospital General Universitario de Albacete
Albacete, Albacete, Spain
Hospital Universitario De Burgos
Burgos, Burgos, Spain
Hospital Universitario Infanta Leonor- Madrid
Madrid, Madrid, Spain
Hospital Clinico Universitario de Valencia
Valencia, València, Spain
Hospital Universitario 12 de Octubre
Madrid, Spain
University Hospital Virgen Del Rocio S.L.
Seville, Spain
Hospital Universitario Y Politecnico La Fe
Valencia, Spain
National Taiwan University Hospital
Taipei, Taipei, Taiwan
Kura Medical Information
844-KURAONC (844-587-2662)
medinfo@kuraoncology.com
Not Provided